

Product Information

Product ID P200000

CAS No. 1196109-52-0

Chemical Name N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide hydrate

Synonym PF3845

Formula C₂₄H₂₃F₃N₄O₂

Formula Wt. 456.47

Melting Point


Purity ≥98%

Solubility DMSO (>45 mg/mL)

Store Temp -20°C

Ship Temp Ambient

Description PF-3845 is an inhibitor of fatty acid amide hydrolase (FAAH). PF-3845 shows anti-allodynic effects in mice stimulated with LPS. It generates this effect without displaying any cannabinolic effects, making it a target for inflammatory pain management. When PF-3845 is used in tandem with the monoacylglycerol lipase (MAGL) inhibitor JZL184, it lessens withdrawal effects from opioid-dependent mice and produces anti-nociceptive effects without cannabimimetic side effects. Studies of PF-3845 treatment for traumatic brain injury in mice showed that PF-3845 lessened impairments found in control mice.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
P200000	5 mg	\$129.60
P200000	25 mg	\$477.00
P200000	100 mg	\$1335.50

References Booker L, Kinsey SG, Abdullah RA et al. The fatty acid hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. *Br J Pharmacol*. 2012 Apr;165(8):2485-96. PMID: 21506952.

Ramesh D, Gamage TF, Vanuytsel T et al. Dual Inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. *Neuropsychopharmacology*. 2013 May;38(6):1039-49. PMID: 23303065

Tchantchou F, Tucker LB, Fu AH, et al. The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. *Neuropharmacology*. 2014 Oct;85:427-39. PMID: 24937045

Ghosh S, Kinsey SG, Liu QS et al. Full Fatty ACid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice. *J Pharmacol Exp Ther*. 2015 Aug;354(2):111-20. PMID25998048.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.